Bahriye Aktas

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients

Bahriye Aktas, Mitra Tewes, Tanja Fehm et al. · Breast Cancer Research · 2009 · 729 citations · Full text

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial

Michael Untch, Christian Jackisch, Andreas Schneeweiß et al. · The Lancet Oncology · 2016 · 408 citations

Breast Oncology, Oncology, Early Breast Cancer +7

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2016 · 357 citations

HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial

Tanja Fehm, Volkmar Müller, Bahriye Aktas et al. · Breast Cancer Research and Treatment · 2010 · 355 citations

Tumor Biology, Her2 Status, Metastatic Breast Cancer +10